Feature | May 17, 2013

First Implant Made for Barostim neo Device to Treat Hypertension

It is designed to use the body's own natural blood flow regulation system to treat hypertension.

May 17, 2013 — Prof. Dr. Béla Merkely and Dr. Péter Sótonyi at Semmelweis Egyetem Kardiológiai Központ in Hungary completed the first patient implant of the Barostim neo device for hypertension. Barostim neo is a small, easy to implant device manufactured by CVRx.

Barostim neo is designed to use the body's own natural blood flow regulation system to treat hypertension. The system works by electrically activating baroreceptors, the body's natural blood pressure sensors that regulate cardiovascular function. When the Barostim neo is activated, signals are sent through neural pathways to the brain, which responds by telling the arteries to relax, the heart to slow down and the kidneys to reduce fluid in the body, lowering excessive blood pressure and workload on the heart.

“Barostim Therapy will provide clinical benefits to our patients in a cost-effective manner. Studies on the device have shown significant, sustained blood pressure reduction which can help reduce the health risks associated with hypertension, such as stroke and kidney failure, and help improve an individual's quality of life,” said Merkely, director at Semmelweis Egyetem Kardiológiai Központ

Barostim neo is a second-generation device that uses CVRx-patented technology that is designed to trigger the body's own natural blood flow regulation system to treat hypertension and heart failure. The system works by electrically activating the baroreceptors, the body's natural blood pressure sensors that regulate cardiovascular function. These baroreceptors are located on the carotid artery. When activated by Barostim neo, signals are sent through neural pathways to the brain, which responds by telling the:

  • Arteries to relax, making it easier for blood to flow through the body and reducing cardiac exertion;
  • Heart to slow down, allowing more time for the organ to fill with blood; and
  • Kidneys to reduce fluid in the body, lowering both excessive blood pressure and workload on the heart.

This patented technology has the potential to improve quality of life and reduce health risks associated with hypertension and heart failure, including heart and kidney disease, stroke and death. Other potential benefits of Barostim neo include that it:

  • Can be adjusted to meet each patient's individual therapy needs, making it the only personalized medical device therapy for the treatment of hypertension with a CE marking;
  • Is a non-destructive reversible treatment; and
  • Provides 100% compliance to treatment, by automatically and continuously activating the baroreflex.

 

For more information: www.cvrx.com

Related Content

Feature | Business| April 28, 2016 | Dave Fornell
 
Technology | Stents Peripheral| April 27, 2016
Veniti Inc. announced the first successful treatment with the Vici Verto Venous Stent System of a patient suffering...
Auris Surgical Robotics, acquisition, Hansen Medical
News | Robotic Systems| April 26, 2016
Auris Surgical Robotics Inc. and Hansen Medical Inc. announced that they have signed a definitive merger agreement...
Siemens Sensis Vibe, hemodyanamics system

Siemens released the Sensis Vibe hemodyanamics system at ACC.16. The newer system offers better integration of cath lab data into cath lab reports and the electronic medical record (EMR).

Feature | ACC| April 25, 2016 | Jon Brubaker, MBA, RCVT, Tom Watson, BS, RCVT, and Sabrina Newell MS, RCS
There were several trends seen in new cardiovascular technologies showcased on the expo floor at the 2016 American...
Medtronic, Drug-Filled Stent, RevElution Trial results, ACC.16, CE Mark
News | Stents Drug Eluting| April 21, 2016
Medtronic plc announced new clinical data from one of the endpoints in the RevElution Trial for its novel, next-...
statins, heart disease, HOPE-3 trial, intermediate-risk patients, hypertension, ACC.16
News | Pharmaceuticals| April 20, 2016
Lowering cholesterol with statins significantly reduced adverse cardiovascular events in people with average...
Boston Scientific, Fetch 2 aspiration catheter, Class 1 recall
News | Thrombectomy Devices| April 20, 2016
April 20, 2016 — Boston Scientific Corp. announced a U.S.
ischemic postconditioning, STEMI patients, clinical outcomes, ACC.16
News | Cath Lab| April 19, 2016
A large randomized controlled trial of ischemic postconditioning in patients who had experienced ST-segment elevation...
STEMI, delayed or deferred stent implantation, DANAMI-3-DEFER trial, ACC.16
News | Cath Lab| April 18, 2016
Delayed or deferred stent implantation in patients showed no clinical benefit in patients experiencing the deadliest...
ACR, American College of Radiology, MEDCAC, peripheral arterial disease, PAD, seniors
News | Peripheral Arterial Disease (PAD)| April 18, 2016
The American College of Radiology (ACR), as a member of a coalition of leading medical societies, provided peripheral...
Overlay Init